“Biogen Reports Its Alzheimer’s Drug Sharply Slowed
Cognitive Decline”
By:
Andrew Pollack
Source:
New York Times
http://www.nytimes.com/2015/03/21/business/alzheimers-drug-trial-shows-cognitive-decline-sharply-slowed.html?ref=science&_r=0
A new experimental drug has for
Alzheimer’s disease has slowed the decline of mental function. The drug was
created by a man named Biogen Idec and is called aducanumab. Although the drug
can have a significant impact on mental function, it can rarely be taken in
high doses, which means the time it will take to improve an individual’s
condition will take a while. However, Alzheimer specialists continue to be
cautious of the new drug claiming that most drugs that are claimed to help with
the disorder end up not working properly. Aducanumab is designed to get rid of
amyloid plaque in the patient’s brain, which is believed to be the cause of
dementia. The main concern about this drug is if it will be effective in a
larger trial, due to the fact that most drugs for this disorder only work on
small trials, not large ones. To further increase the drug’s chance of success,
Biogen tried to give the drug to patients who are in the early stages of the
disease. In general, the drug slows cognitive decline and reduces plaque in the
brain. Higher doses did prove to be better than lower doses, but can only be
used for a short amount of time.
This new drug may be a way to find
a cure to individuals with Alzheimer’s disease. Although this new drug has
created hope for many scientists, they should not rush into believing this drug
is the cure. The drug only slows cognitive decline; it does not stop it.